Analysts See $-0.88 EPS for Merus N.V. (MRUS) as of July, 10

June 27, 2018 - By Mark Williams

Merus N.V. (NASDAQ:MRUS)’s earnings release is anticipated by WallStreet on July, 10, Zacks reports. Analysts forecast 28.46 % diference or $-0.88 from the $-1.23 EPS from 2017. After $-0.86 EPS report last quarter, Wall Street now sees 2.33 % negative EPS growth of Merus N.V.. Ticker’s shares touched $20.83 during the last trading session after 2.61% change.Currently Merus N.V. is downtrending after 2.28% change in last June 27, 2017. MRUS has 19,743 shares volume. MRUS underperformed by 14.85% the S&P500.

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics.The firm is valued at $471.27 million. The Company’s lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, gastric, and ovarian cancers.Currently it has negative earnings. The firm also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies, as well as developing MCLA-158, a bispecific antibody candidate, which is designed to bind to cancer stem cells for the potential treatment of colorectal cancer.

More recent Merus N.V. (NASDAQ:MRUS) news were published by Benzinga.com, Globenewswire.com and Globenewswire.com. The first one has “Benzinga’s Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street” as a title and was published on June 21, 2018. The next is “Merus to Present at the Jefferies 2018 Healthcare Conference” on May 31, 2018. And last was published on June 06, 2018, called “Analysis: Positioning to Benefit within China Biologic Products, Merus NV, Adient, G1 Therapeutics, Westport Fuel, and …”.

Merus N.V. (NASDAQ:MRUS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.